EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Phase 1 clinical trial of eneboparatide, a novel PTH receptor 1 agonist

Michel Ovize iD, Soraya Allas, Michael D Culler, Stephane Milano, Taha Ouldrouis, Mark Sumeray iD, Jeroen van de Wetering de Rooij, Michael Mannstadt

Endocrine Connections · 01.06.2025 · 14 (6)

DOI: 10.1530/ec-24-0464 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Endocrine Connections, online erschienen am 27.05.2025. Verfasst von Michel Ovize und 7 weiteren Autor:innen. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

This study evaluated the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of eneboparatide (AZP-3601), a novel agonist of the PTH receptor 1 developed for the treatment of hypoparathyroidism.

Design

This was a randomized, double-blind, placebo-controlled study. One-hundred four healthy volunteers were recruited into seven single ascending dose (SAD) and five multiple ascending dose (MAD) cohorts.

Methods

PK parameters were time to peak, Cmax, area under the curve (AUC) and half-life. PD parameters included albumin-adjusted serum calcium (sCa), serum phosphorus (sPh), serum endogenous PTH, 24 hr urinary excretion of calcium (24 h-uCa), fractional excretion of calcium (FECa) and bone turnover markers (s-CTX and P1NP).

Results

There were no serious adverse events. All adverse events were of mild-to-moderate intensity. AUC and Cmax of eneboparatide increased with increasing doses. Time to maximum plasma concentration was 5–20 min. SAD showed a dose-dependent increase of sCa and decrease of sPh associated with a reduction of serum endogenous PTH. MAD demonstrated a rapid access to maximal PD effects and maintained levels of sCa throughout the day. Urinary excretion of calcium did not increase as a function of the dose of eneboparatide. P1NP and s-CTX did not change over the treatment period.

Conclusion

The PD effects of eneboparatide were prolonged despite the short half-life. These data suggest that eneboparatide may provide sustained control of serum calcium in patients with hypoparathyroidism with once daily dosing. An open-label phase 2 study in patients with hypoparathyroidism has been recently completed and published and a phase 3 study has been initiated. Clinical Trial Registration Number NCT05239221.

Schlagwörter

Stichwörter der Autor:innen

bonecalciumhypoparathyroidismkidneyparathormone

Autor:innen und Institutionen

ORCID-Profile: Michel Ovize, Mark Sumeray

Zitieren

APA

Ovize, M., Allas, S., Culler, M. D., Milano, S., Ouldrouis, T., Sumeray, M., van de Wetering de Rooij, J., & Mannstadt, M. (2025). Phase 1 clinical trial of eneboparatide, a novel PTH receptor 1 agonist. Endocrine Connections, 14(6). https://doi.org/10.1530/ec-24-0464

Vancouver

Ovize M, Allas S, Culler MD, Milano S, Ouldrouis T, Sumeray M, et al. Phase 1 clinical trial of eneboparatide, a novel PTH receptor 1 agonist. Endocrine Connections. 2025;14(6). doi:10.1530/ec-24-0464

BibTeX
@article{Ovize2025,
  author = {Ovize, Michel and Allas, Soraya and Culler, Michael D and Milano, Stephane and Ouldrouis, Taha and Sumeray, Mark and van de Wetering de Rooij, Jeroen and Mannstadt, Michael},
  title = {Phase 1 clinical trial of eneboparatide, a novel PTH receptor 1 agonist},
  journal = {Endocrine Connections},
  year = {2025},
  volume = {14},
  number = {6},
  doi = {10.1530/ec-24-0464}
}
Kostenlos starten →